SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Lpath Inc.
An SI Board Since December 2011
Posts SubjectMarks Bans Symbol
6 3 0 LPTN
Emcee:  Pistol Pete Type:  Moderated
Introduction Market Data Compact
Lpath, Inc., a biotechnology company, engages in the discovery and development of lipidomic-based therapeutic antibodies to treat human diseases in the United States. Its product candidate includes iSONEP, an ocular formulation of Sonepcizumab, which is a humanized monoclonal antibody (mAb) against sphingosine-1-phosphate for wet age-related macular degeneration (wet AMD), diabetic retinopathy, dry AMD, and glaucoma-related surgery. The company?s product candidate also comprises ASONEP, a systemic formulation of sonepcizumab for the treatment of cancer, which has completed a Phase I clinical trial. Its pre-clinical product candidate includes Lpathomab, a mAb against lysophosphatidic acid for the treatment of cancer, fibrosis, and neuropathic pain. The company was founded in 1997 and is based in San Diego, California.

This forum was created for people to dicuss LPTN news and share information gathered from other sites.
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News